Core 2: PDX Tumor Core

摘要(患者来源的异种移植核) 患者衍生的异种移植(PDX)核心将支持芝加哥地区-PSOC为定义 染色质的时空组织通过提供CR-PSOC在肿瘤信息传递中的作用 研究人员拥有一个有价值的人类癌症模型，使研究人员能够扩大他们的观察范围 到真正的病人肿瘤细胞。核心将创造和维护仔细描绘的活体人类肿瘤 广泛的组织学模型，保留了新鲜人类肿瘤的特征。这些PDX 模型在体内连续传代，从未接触过组织培养塑料及其局限性 由某些肿瘤细胞克隆的组织培养选择所强加的。PDX肿瘤保留组织学 与患者肿瘤相似的特征。因此，这些模型是 被认为比传统的异种移植模型更接近临床情况。型号将提供给 调查人员横跨PS-On。 核心将建立在已经建立的PDX储存库基础设施上，该基础设施目前维护62个 覆盖10种不同肿瘤组织的模型，每周创建2-3个新模型。及早通过 细胞系是从这些体内PDX模型并行创建的，它们也将用于CR-PSOC 调查人员，以及潜在的PS-ON调查人员。这些早期传代的细胞系将被利用 用于所有三个CR-PSOC研究项目的体外实验。表型和遗传型的一致性 这些单元格将支持跨三个项目的数据集成。PDX核心将提供组织和 从现有的乳腺癌和胶质瘤PDX到项目1研究人员的体内可用的细胞系 亚细胞金属组失衡的特征作为潜在的致瘤性的定量标志。在……里面 此外，Core将创建新的人类多发性骨髓瘤和髓母细胞瘤的PDX模型，因为 钾失衡与这些类型肿瘤的发生和发展有关。PDX 模型也将被项目1的研究人员用于成像研究和评估治疗潜力 靶向K+通道的研究为成像研究提供了支持。Core将发展为急性髓系白血病(AML) 与膀胱癌PDX模型和细胞增强子关系的研究 功能障碍和癌症。核心将为项目3调查人员提供来自各种PDX的细胞系 为了能够确定凝聚素、粘附素和SMC5/6的分布的变化关系 人类肿瘤间期和有丝分裂过程中的染色体与染色体力学的变化 单元类型。

ABSTRACT (PATIENT-DERIVED XENOGRAFT CORE) The Patient-Derived Xenograft (PDX) Core will support the efforts of the Chicago Region-PSOC to define the role of the spatio-temporal organization of chromatin in information transfer in cancer by providing CR-PSOC investigators with a valuable model of human cancer that will enable investigators to extend their observations to actual patient tumor cells. The Core will create and maintain carefully delineated, in vivo human tumor models from a broad range of histologies that retain the characteristics of fresh human tumors. These PDX models are passaged continuously in vivo and are never exposed to tissue culture plastic and the limitations imposed by tissue culture selection of certain tumor cell clones. The PDX tumors retain histological characteristics that are similar to the patient tumors from which they were derived. Thus, these models are thought to be closer to the clinical situation than traditional xenograft models. Models will be available to investigators across the PS-ON. The Core will build on an already established PDX repository infrastructure that currently maintains sixty-two models covering ten different tumor histologies, with 2-3 new models are created each week. Early passage cell lines are created in parallel from these in vivo PDX models and they will also be available to the CR-PSOC investigators, as well as potentially to investigators in the PS-ON. These early passage cell lines will be utilized for in vitro experiments by all three CR-PSOC research projects. The phenotypic and genotypic uniformity of these cells will enable integration of data that across the three projects. The PDX Core will provide tissue and cell lines, where available, from existing breast cancer and glioma PDX to Project 1 investigators for in vivo characterization of subcellular metallome imbalances as potential quantitative markers of tumorigenicity. In addition, the Core will create new PDX models of human multiple myeloma and medulloblastoma since potassium imbalances have been implicated in the tumorigenicity and progression of these tumor types. PDX models will also be used by Project 1 investigators for imaging studies and to evaluate the therapeutic potential of targeting K+ channels support the imaging studies. The Core will develop acute myeloid leukemia (AML) and bladder cancer PDX models and cells for use by Project 2 to study the relationship between enhancer dysfunction and cancer. The Core will provide Project 3 investigators with cell lines derived from various PDX to enable determination of the relationship of variation of the distribution of condensin, cohesin, and SMC5/6 in chromosomes during interphase and mitosis with variations in chromosome mechanics across human tumor cell types.